From £7.99 per month
ShareProphets
The one stop source for breaking news, expert analysis, and podcasts on fast-moving AIM and LSE listed shares

MINDING THE LSE’S BUSINESS

Join for as low as £7.99 per month

With ShareProphets’ membership, you receive:

• All premium articles

• Tom Winnifrith’s Bearcast

• Access to all the entire nearly 10 year archive

• ShareProphets Daily Newsletter

Shocking news at InVMA which Tern is not disclosing via RNS. Who cares about AIM Rules anyway?

By Nigel Somerville, the Deputy Sheriff of AIM | Wednesday 9 December 2020


Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from ShareProphets). I have no business relationship with any company whose stock is mentioned in this article.


Shares in AIM-listed jam-tomorrow (if ever) investment company have again been dribbling south, closing yesterday at 6.95p. With a load of freshly raised cash and a new investment to boast, surely things are going well for Tern……but alas the market seems to be taking a different view. Of course, Tern has a habit of keeping quiet when there might be something to clear up – such as the recent speculation (unfounded, as it happens) on the BBs about Wyld. And that brings me to its 50%-owned investee InVMA.

Premium content is for paid subscribers only
ShareProphets is reader-supported journalism

Become a member starting at £6.99 per month for all articles, the Bearcast, and our seven year archive.


Filed under:



Subscribe to our newsletter

Daily digest of our latest stories.



Search ShareProphets

Market News

Complete Coverage

Recent Comments

That Was the Week that Was

 

AAU

Gold up Ariana down

Saturday »

AVCT

Cassava, A warning to Avacta Sharehoders 

Friday »

ALU

Alumasc Group – a growth Buy

 

VCP

Victoria - The roll up unravels

 

HEMO

Hemogenyx is a short – target 0p

 

ECR

ECR, the timing is unfortunate

 

APH

Alliance Pharma – a recovery Buy?

Time left: 09:49:08